{"id":"azd0530-difumarate","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL2103739","moleculeType":"Small molecule","molecularWeight":"534.57"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"AZD0530 (saracatinib) inhibits Src family kinases, which are non-receptor tyrosine kinases implicated in various cancers and inflammatory diseases. By blocking Src kinase activity, the drug disrupts downstream signaling cascades that promote tumor cell growth, survival, and migration. This mechanism has been explored in multiple cancer types and other conditions where Src activation contributes to pathology.","oneSentence":"AZD0530 is a Src family kinase inhibitor that blocks intracellular signaling pathways involved in cell proliferation and survival.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:30:15.949Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (Phase 2 investigational)"}]},"trialDetails":[{"nctId":"NCT01216176","phase":"PHASE1, PHASE2","title":"A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer","status":"COMPLETED","sponsor":"Joyce Marie Slingerland, MD","startDate":"2008-10-21","conditions":"Breast Cancer","enrollment":71},{"nctId":"NCT04307953","phase":"PHASE2","title":"Saracatinib Trial TO Prevent FOP","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2020-08-05","conditions":"Fibrodysplasia Ossificans Progressiva","enrollment":20},{"nctId":"NCT00265876","phase":"PHASE1, PHASE2","title":"AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2006-04-26","conditions":"Pancreatic Cancer","enrollment":34},{"nctId":"NCT02262026","phase":"PHASE1","title":"The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-11-01","conditions":"Alcoholism","enrollment":49},{"nctId":"NCT01864655","phase":"PHASE1","title":"Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease","status":"COMPLETED","sponsor":"Stephen M. Strittmatter","startDate":"2013-07","conditions":"Alzheimer's Disease","enrollment":24},{"nctId":"NCT02955186","phase":"PHASE2","title":"Saracatinib and Alcohol Drinking","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-05-09","conditions":"Alcohol Drinking","enrollment":50},{"nctId":"NCT02737202","phase":"PHASE2","title":"Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2016-04","conditions":"Pulmonary Lymphangioleiomyomatosis","enrollment":28},{"nctId":"NCT00752206","phase":"PHASE2","title":"A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung","status":"TERMINATED","sponsor":"Sarcoma Alliance for Research through Collaboration","startDate":"2009-03","conditions":"Osteosarcoma","enrollment":38},{"nctId":"NCT02732587","phase":"PHASE1","title":"Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers","status":"COMPLETED","sponsor":"Yale University","startDate":"2015-11","conditions":"Alcohol Drinking","enrollment":5},{"nctId":"NCT00397878","phase":"PHASE2","title":"AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-11","conditions":"Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":10},{"nctId":"NCT02167256","phase":"PHASE2","title":"A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-12","conditions":"Alzheimer's Disease","enrollment":159},{"nctId":"NCT03661125","phase":"EARLY_PHASE1","title":"SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis","status":"UNKNOWN","sponsor":"King's College London","startDate":"2019-04-11","conditions":"Parkinson Disease Psychosis","enrollment":30},{"nctId":"NCT00735917","phase":"PHASE2","title":"Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-10","conditions":"Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer","enrollment":19},{"nctId":"NCT00638937","phase":"PHASE2","title":"AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02","conditions":"Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":37},{"nctId":"NCT00607594","phase":"PHASE2","title":"Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-01","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer","enrollment":21},{"nctId":"NCT00659360","phase":"PHASE2","title":"AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02","conditions":"Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma","enrollment":17},{"nctId":"NCT00513071","phase":"PHASE2","title":"AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-08","conditions":"Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer","enrollment":28},{"nctId":"NCT00528645","phase":"PHASE2","title":"AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-11","conditions":"Extensive Stage Small Cell Lung Cancer, Lung Metastases, Malignant Pleural Effusion","enrollment":23},{"nctId":"NCT02116712","phase":"PHASE1","title":"The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)","status":"COMPLETED","sponsor":"Tony Eissa","startDate":"2014-08","conditions":"Pulmonary Lymphangioleiomyomatosis","enrollment":9},{"nctId":"NCT00718809","phase":"PHASE2","title":"Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-06","conditions":"Invasive Thymoma and Thymic Carcinoma, Recurrent Thymoma and Thymic Carcinoma, Stage III Thymoma","enrollment":21},{"nctId":"NCT01196741","phase":"PHASE2, PHASE3","title":"Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer","status":"COMPLETED","sponsor":"University College, London","startDate":"2011-03","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":107},{"nctId":"NCT01267266","phase":"PHASE2","title":"Saracatinib in Treating Patients With Prostate Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-12","conditions":"Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer","enrollment":31},{"nctId":"NCT00669019","phase":"PHASE2","title":"Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-07","conditions":"Recurrent Melanoma, Stage IIA Melanoma, Stage IIB Melanoma","enrollment":23},{"nctId":"NCT00559507","phase":"PHASE2","title":"Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-10","conditions":"Estrogen Receptor-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer","enrollment":12},{"nctId":"NCT00513435","phase":"PHASE2","title":"Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-07","conditions":"Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx","enrollment":9},{"nctId":"NCT00558272","phase":"PHASE2","title":"Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-02","conditions":"Breast Cancer, Prostate Cancer, Bone Neoplasms","enrollment":139},{"nctId":"NCT00610714","phase":"PHASE2","title":"AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Ovarian Neoplasms, Ovarian Cancer","enrollment":211},{"nctId":"NCT00704366","phase":"PHASE1","title":"AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-06","conditions":"Solid Tumor","enrollment":18},{"nctId":"NCT00496028","phase":"PHASE1","title":"Phase I Study in Patients With Solid Tumours","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-03","conditions":"Neoplasms","enrollment":148},{"nctId":"NCT00475956","phase":"PHASE1","title":"Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-05","conditions":"Neoplasms","enrollment":40},{"nctId":"NCT01000896","phase":"PHASE1","title":"Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Cancer, Non Small Cell Lung Cancer, Epithelial Ovarian Cancer","enrollment":27},{"nctId":"NCT00771979","phase":"PHASE1","title":"Relative Bioavailability of Phase II and Phase III Formulations of AZD0530","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Healthy","enrollment":18},{"nctId":"NCT00853983","phase":"PHASE1","title":"Phase I Study to Assess Absorption, Metabolism & Excretion of a Single Oral Dose [14C]AZD0530 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-03","conditions":"Healthy","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Saracatinib"],"phase":"phase_2","status":"active","brandName":"AZD0530 Difumarate","genericName":"AZD0530 Difumarate","companyName":"Amsterdam UMC, location VUmc","companyId":"amsterdam-umc-location-vumc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD0530 is a Src family kinase inhibitor that blocks intracellular signaling pathways involved in cell proliferation and survival. Used for Advanced solid tumors (Phase 2 investigational).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}